Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | GLS | O94925 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30657544 | 0.91 | CYP1B1 (0.56) | CYP1B1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL17525790 | 0.91 | CYP1B1 (0.56) | CYP1B1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL28872170 | 0.91 | CYP1B1 (0.52) | CYP1B1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL383479 | 0.91 | CYP1B1 (0.52) | CYP1B1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL19406784 | 0.91 | CYP1B1 (0.52) | CYP1B1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL23439163 | 0.91 | CYP1B1 (0.52) | CYP1B1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL383480 | 0.91 | CYP1B1 (0.52) | CYP1B1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL5073226 | 0.91 | CYP1B1 (0.52) | CYP1B1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL21598051 | 0.91 | CYP1A2 (0.54) | CYP1B1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL19398815 | 0.91 | CYP1B1 (0.52) | CYP1B1CYP1A2CYP2C9CYP2C19ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101107228-B | Process for producing (Z)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2-phthalimidomethylcyclopropane | SUMITOMO CHEMICAL CO | 2011-04-13 | — | — | CN | claimed |
| CN-101107228-A | Process for producing (Z)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2-phthalimidomethylcyclopropane | SUMITOMO CHEMICAL CO (JP) | 2008-01-16 | — | — | CN | claimed |
| CN-115109012-A | Benzyl arylamine aldehyde dehydrogenase agonist, and synthesis method and application thereof | 中国人民解放军海军军医大学 | 2022-09-27 | — | — | CN | disclosed |
| WO-2019204477-A1 | PD(II)-CATALYZED ENANTIOSELECTIVE C-H ARYLATION OF FREE CARBOXYLIC ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-10-24 | — | — | WO | disclosed |
| EP-3333169-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2018-06-13 | — | — | EP | disclosed |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20110130576-A1 | PROCESS FOR PRODUCING (Z)-1-PHENYL-1-(N,N-DIETHYLAMINOCARBONYL)-2-PHTHALIMIDOMETHYLCYCLOPROPANE | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-06-02 | — | — | US | disclosed |
| US-7943785-B2 | Process for producing (Z)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2- phthalimidomethylcyclopropane | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| EP-1845084-B1 | PROCESS FOR PRODUCING (Z)-1-PHENYL-1-(N,N-DIETHYLAMINOCARBONYL)IDOMETHYLCYCLOPROPANE | SUMITOMO CHEMICAL CO (JP) | 2011-04-20 | — | — | EP | disclosed |
| CN-101107228-B | Process for producing (Z)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2-phthalimidomethylcyclopropane | SUMITOMO CHEMICAL CO | 2011-04-13 | — | — | CN | disclosed |
| CN-101107228-A | Process for producing (Z)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2-phthalimidomethylcyclopropane | SUMITOMO CHEMICAL CO (JP) | 2008-01-16 | — | — | CN | disclosed |
| EP-1845084-A1 | PROCESS FOR PRODUCING (Z)-1-PHENYL-1-(N,N-DIETHYLAMINOCARBONYL)IDOMETHYLCYCLOPROPANE | Sumitomo Chemical Company, Limited (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-7078428-B2 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-18 | — | — | US | disclosed |
| US-20060148880-A1 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
| EP-1528923-B1 | N-((3-OXO-2,3-DIHYDRO-1H-ISOINDOL-1-YL)ACETYL)GUANIDINE DERIVATIVES AS NHE1-INHIBITORS FOR THE TREATMENT OF INFARCTION AND ANGINA PECTORIS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-05-03 | — | — | EP | disclosed |
| EP-1528923-A1 | N-((3-OXO-2,3-DIHYDRO-1H-ISOINDOL-1-YL)ACETYL)GUANIDINE DERIVATIVES AS NHE1-INHIBITORS FOR THE TREATMENT OF INFARCTION AND ANGINA PECTORIS | Aventis Pharma Deutschland GmbH (DE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040048916-A1 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUSCHLAND GMBH (DE) | 2004-03-11 | — | — | US | disclosed |
| WO-2003101450-A1 | N- ((3-OXO2, 3-DIHYDRO-1H-ISOINDOL-1-YL) ACETYL) GUANIDINE DERIVATIVES AS NHE-1 INHIBITORS FOR THE TREATMENT OF INFARCTION AND ANGINA PECTORIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-11 | — | — | WO | disclosed |
| WO-2002040445-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | CYP1B1 1034/4885CYP1A2 1089/4885CYP2C9 1806/4885 |
| US-20110130576-A1 | PROCESS FOR PRODUCING (Z)-1-PHENYL-1-(N,N-DIETHYLAMINOCARBONYL)-2-PHTHALIMIDOMETHYLCYCLOPROPANE | BPNT1, CPN1, PNN | CYP1B1 86/4885CYP1A2 865/4885CYP2C9 480/4885 |
| US-20060148880-A1 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | TNNI3, NDUFB3, NDUFB11 | CYP1B1 130/4885CYP1A2 99/4885CYP2C9 425/4885 |
| US-20040048916-A1 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | TNNI3, NDUFB3, NDUFB11 | CYP1B1 113/4885CYP1A2 111/4885CYP2C9 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.